Mark Stenhouse - 01 Jun 2023 Form 4 Insider Report for Prometheus Biosciences, Inc.

Role
Chief Operating Officer
Signature
/s/ Timothy K. Andrews, attorney-in-fact for Mark Stenhouse
Issuer symbol
N/A
Transactions as of
01 Jun 2023
Net transactions value
$0
Form type
4
Filing time
02 Jun 2023, 18:57:01 UTC
Previous filing
30 May 2023
Next filing
16 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXDX Common Stock Other $0 -14,000 -52% $0.000000 12,708 01 Jun 2023 Direct F1, F2
transaction RXDX Common Stock Other $0 +14,000 $0.000000 14,000 01 Jun 2023 By Stenhouse Family Fund F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transfer of shares from the Reporting Person to the Stenhouse Family Fund, a Charitable Gift Fund (the "Stenhouse Family Fund").
F2 Includes a total of 266 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
F3 The Reporting Person is a Donor of the Stenhouse Family Fund.